The Effects of Four Different Tyrosine Kinase Inhibitors on Medullary and Papillary Thyroid Cancer Cells

• Published in: The journal of clinical endocrinology and metabolism Vol. 96; no. 6; pp. E991 - E995
• Main Authors: Verbeek, Hans H. G, Alves, Maria M, de Groot, Jan-Willem B, Osinga, Jan, Plukker, John T. M, Links, Thera P, Hofstra, Robert M. W
• Format: Journal Article
• Language: English
• Published: United States Endocrine Society 01.06.2011
• Subjects: Anilides - pharmacology; Axitinib; Blotting, Western; Cell Line, Tumor; Cell Proliferation - drug effects; Humans; Imidazoles - pharmacology; Indazoles - pharmacology; Indoles - pharmacology; Phosphorylation - drug effects; Piperidines - pharmacology; Protein Kinase Inhibitors - pharmacology; Proto-Oncogene Proteins c-ret - metabolism; Pyridines - pharmacology; Pyrroles - pharmacology; Quinazolines - pharmacology; Receptor Protein-Tyrosine Kinases - antagonists & inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction - drug effects; Sunitinib; Thyroid Gland - cytology; Thyroid Gland - drug effects; Thyroid Gland - metabolism; Tumor Cells, Cultured
• ISSN: 0021-972X; 1945-7197
• DOI: 10.1210/jc.2010-2381

Tyrosine kinase inhibitor therapy for medullary and papillary thyroid carcinoma is mutation specific, with XL184 being the most potent inhibitor in MEN2A and papillary thyroid carcinoma, and vandetanib in MEN2B. Context: Medullary and papillary thyroid carcinoma (MTC and PTC) are two types of thyroid cancer that can originate from activating mutations or rearrangements in the RET gene. Therapeutic options are limited in recurrent disease, but because RET is a tyrosine kinase (TK) receptor involved in cellular growth and proliferation, treatment with a TK inhibitor might be promising. Several TK inhibitors have been tested in clinical trials, but it is unknown which inhibitor is most effective and whether there is any specificity for particular RET mutations. Objective: We aimed to compare the effect of four TK inhibitors (axitinib, sunitinib, vandetanib, and XL184) on cell proliferation, RET expression and autophosphorylation, and ERK activation in cell lines expressing a MEN2A (MTC-TT), a MEN2B (MZ-CRC-1) mutation, and a RET/PTC (TPC-1) rearrangement. Design: The three cell lines were cultured and treated with the four TK inhibitors. Effects on cell proliferation and RET and ERK expression and activation were determined. Results: XL184 and vandetanib most effectively inhibited cell proliferation, RET autophosphorylation in combination with a reduction of RET expression, and ERK phosphorylation in MTC-TT and MZ-CRC-1, respectively. TPC-1 cells showed a decrease in RET autophosphorylation after treatment with XL184, but no effect was observed on ERK activation. Conclusion: There is indeed specificity for different RET mutations, with XL184 being the most potent inhibitor in MEN2A and PTC and vandetanib the most effective in MEN2B in vitro. No TK inhibitor was superior for all the cell lines tested, indicating that mutation-specific therapies could be beneficial in treating MTC and PTC.